Systemic chemotherapy and its implications for resection of colorectal liver metastasis

Surgical Oncology

Volumn 20, Issue 2, 2011, Pages 57-72

  Robinson, S ^a   Manas, D M ^a   Pedley, I ^a   Mann, D ^b   White, S A ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Liver resection; Sinusoidal obstruction; Steatohepatitis; Steatosis

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 6; IRINOTECAN; K RAS PROTEIN; MITOMYCIN C; OXALIPLATIN; OXALIPLATIN MEDAC; PANITUMUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; BILIARY TRACT DRAINAGE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL CARCINOMA; GENE MUTATION; HEPATIC ARTERY; HUMAN; KUPFFER CELL; LAPAROTOMY; LIVER CELL; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; LONG TERM CARE; MEDLINE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT PREFERENCE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLEROSING CHOLANGITIS; SENSORY DYSFUNCTION; SKIN MANIFESTATION; STELLATE CELL; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WILD TYPE;

EID: 79954614862     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.10.002     Document Type: Review

References (132)

1. P. Boyle, and J. Ferlay Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 3 2005 Mar 481 488 (Pubitemid 40458328)
2. R. Stangl, A. Altendorf-Hofmann, R.M. Charnley, and J. Scheele Factors influencing the natural history of colorectal liver metastases Lancet 343 8910 1994 Jun 4 1405 1410 (Pubitemid 24167517)
3. C.B. Wood, C.R. Gillis, and L.H. Blumgart A retrospective study of the natural history of patients with liver metastases from colorectal cancer Clin Oncol 2 3 1976 Sep 285 288
4. G. Bengtsson, G. Carlsson, L. Hafstrom, and P.E. Jonsson Natural history of patients with untreated liver metastases from colorectal cancer Am J Surg 141 5 1981 May 586 589 (Pubitemid 11099239)
5. R. Lochan, S.A. White, and D.M. Manas Liver resection for colorectal liver metastasis Surg Oncol Rev 16 1 2007 Jul 33 45 (Pubitemid 46881287)
6. M. Rees, P.P. Tekkis, F.K. Welsh, T. O'Rourke, and T.G. John Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients Ann Surg 247 1 2008 Jan 125 135
7. P. Kornprat, W.R. Jarnagin, M. Gonen, R.P. DeMatteo, Y. Fong, and L.H. Blumgart Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy Ann Surg Oncol 14 3 2007 Mar 1151 1160
8. M.A. Choti, J.V. Sitzmann, M.F. Tiburi, W. Sumetchotimetha, R. Rangsin, and R.D. Schulick Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 6 2002 Jun 759 766 (Pubitemid 34547293)
9. D.A. Wicherts, R. Miller, R.J. de Haas, G. Bitsakou, E. Vibert, and L.A. Veilhan Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases Ann Surg 248 6 2008 Dec 994 1005
10. G.D. Stewart, C.B. O'Suilleabhain, K.K. Madhavan, S.J. Wigmore, R.W. Parks, and O.J. Garden The extent of resection influences outcome following hepatectomy for colorectal liver metastases Eur J Surg Oncol 30 4 2004 May 370 376 (Pubitemid 38528920)
11. K.J. Halazun, A. Al-Mukhtar, A. Aldouri, H.Z. Malik, M.S. Attia, and K.R. Prasad Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role Ann Surg 246 6 2007 Dec 1065 1074 (Pubitemid 350179201)
12. J.S. Gold, C. Are, P. Kornprat, W.R. Jarnagin, M. Gonen, and Y. Fong Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients Ann Surg 247 1 2008 Jan 109 117
13. E.J. Mullin, M.S. Metcalfe, and G.J. Maddern How much liver resection is too much? Am J Surg 190 1 2005 Jul 87 97 (Pubitemid 40828612)
14. O.J. Garden, M. Rees, G.J. Poston, D. Mirza, M. Saunders, and J. Ledermann Guidelines for resection of colorectal cancer liver metastases Gut 55 Suppl. 3 2006 Aug iii1 iii8
15. R. Vetelainen, R.J. Bennink, A.K. van Vliet, and T.M. van Gulik Mild steatosis impairs functional recovery after liver resection in an experimental model Br J Surg 94 8 2007 Aug 1002 1008 (Pubitemid 47236546)
16. K.E. Behrns, G.G. Tsiotos, N.F. DeSouza, M.K. Krishna, J. Ludwig, and D.M. Nagorney Hepatic steatosis as a potential risk factor for major hepatic resection J Gastrointest Surg 2 3 1998 May-Jun 292 298 (Pubitemid 128409616)
17. Y. Fong, R.L. Sun, W. Jarnagin, and L.H. Blumgart An analysis of 412 cases of hepatocellular carcinoma at a Western center Ann Surg 229 6 1999 Jun 790 799 discussion 9-800
18. C.N. Yeh, M.F. Chen, W.C. Lee, and L.B. Jeng Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis J Surg Oncol 81 4 2002 Dec 195 202
19. D. Gomez, H.Z. Malik, G.K. Bonney, V. Wong, G.J. Toogood, and J.P. Lodge Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis Br J Surg 94 11 2007 Nov 1395 1402 (Pubitemid 350144389)
20. K. Kubota, M. Makuuchi, K. Kusaka, T. Kobayashi, K. Miki, and K. Hasegawa Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors Hepatology 26 5 1997 Nov 1176 1181 (Pubitemid 27509300)
21. M. Makuuchi, B.L. Thai, K. Takayasu, T. Takayama, T. Kosuge, and P. Gunven Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report Surgery 107 5 1990 May 521 527 (Pubitemid 20156653)
22. K. Seymour, R.M. Charnley, J. Rose, C.J. Baudouin, and D.M. Manas Extending the indications for curative liver resection by portal vein embolization Br J Surg 87 3 2000 Mar 362 373
23. A.W. Hemming, A.I. Reed, R.J. Howard, S. Fujita, S.N. Hochwald, and J.G. Caridi Preoperative portal vein embolization for extended hepatectomy Ann Surg 237 5 2003 May 686 691 discussion 91-93
24. R. Adam, A. Laurent, D. Azoulay, D. Castaing, and H. Bismuth Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors Ann Surg 232 6 2000 Dec 777 785
25. N. Neeleman, and R. Andersson Repeated liver resection for recurrent liver cancer Br J Surg 83 7 1996 Jul 893 901 (Pubitemid 26228200)
26. H. Imamura, Y. Seyama, N. Kokudo, A. Maema, Y. Sugawara, and K. Sano One thousand fifty-six hepatectomies without mortality in 8 years Arch Surg 138 11 2003 Nov 1198 1206 discussion 206 (Pubitemid 37392393)
27. C. Kelly, and J. Cassidy Chemotherapy in metastatic colorectal cancer Surg Oncol 16 1 2007 Jul 65 70 (Pubitemid 46880340)
28. M.A. Poon, M.J. O'Connell, C.G. Moertel, H.S. Wieand, S.A. Cullinan, and L.K. Everson Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma J Clin Oncol 7 10 1989 Oct 1407 1418 (Pubitemid 19245110)
29. W. Scheithauer, H. Rosen, G.V. Kornek, C. Sebesta, and D. Depisch Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 306 6880 1993 Mar 20 752 755 (Pubitemid 23080053)
30. D.I. Jodrell, M. Stewart, R. Aird, G. Knowles, A. Bowman, and L. Wall 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer Br J Cancer 84 5 2001 Mar 2 600 603 (Pubitemid 32238991)
31. A. De Gramont, M. Krulik, J. Cady, B. Lagadec, J.E. Maisani, and J.P. Loiseau High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer Eur J Cancer Clin Oncol 24 9 1988 Sep 1499 1503
32. Meta-analysis Group In Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1 1998 Jan 301 308
33. H. Cure, V. Chevalier, A. Adenis, N. Tubiana-Mathieu, G. Niezgodzki, and F. Kwiatkowski Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer J Clin Oncol 20 5 2002 Mar 1 1175 1181 (Pubitemid 34177422)
34. E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, and M. Boyer Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 21 2001 Nov 1 4097 4106 (Pubitemid 33049527)
35. P.M. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, and M. Kuperminc Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 8 2001 Apr 15 2282 2292 (Pubitemid 32366981)
36. D. Machover, E. Diaz-Rubio, A. de Gramont, A. Schilf, J.J. Gastiaburu, and S. Brienza Two consecutive phase II studies of Oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 1 1996 Jan 95 98 (Pubitemid 26051870)
37. F. Levi, B. Perpoint, C. Garufi, C. Focan, P. Chollet, and P. Depres-Brummer Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate Eur J Cancer 29A 9 1993 1280 1284 (Pubitemid 23169897)
38. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, and J. Cassidy Leucovorin and fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 Aug 2938 2947 (Pubitemid 30644117)
39. G. Folprecht, A. Grothey, S. Alberts, H.R. Raab, and C.H. Kohne Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 8 2005 Aug 1311 1319 (Pubitemid 41158476)
40. D. Cunningham, S. Pyrhonen, R.D. James, C.J. Punt, T.F. Hickish, and R. Heikkila Randomised trial of Irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 9138 1998 Oct 31 1413 1418 (Pubitemid 28510874)
41. P. Rougier, E. Van Cutsem, E. Bajetta, N. Niederle, K. Possinger, and R. Labianca Randomised trial of Irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 9138 1998 Oct 31 1407 1412 (Pubitemid 28510873)
42. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, and M.J. Moore Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 2000 Sep 28 905 914
43. E. Maiello, V. Gebbia, F. Giuliani, G. Paoletti, N. Gebbia, and S. Cigolari 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group Ann Oncol 11 8 2000 Aug 1045 1051
44. H.P. Kalofonos, G. Aravantinos, P. Kosmidis, P. Papakostas, T. Economopoulos, and M. Dimopoulos Irinotecan or Oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study Ann Oncol 16 6 2005 Jun 869 877 (Pubitemid 40903911)
45. G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, and N. Gebbia Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 23 22 2005 Aug 1 4866 4875 (Pubitemid 46223991)
46. A.M. Jubb, T.Q. Pham, A.M. Hanby, G.D. Frantz, F.V. Peale, and T.D. Wu Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours J Clin Pathol 57 5 2004 May 504 512 (Pubitemid 38621796)
47. N. Ferrara, and T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1 1997 Feb 4 25 (Pubitemid 27076453)
48. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.[see comment] N Engl J Med 350 23 2004 Jun 3 2335 2342 [Clinical Trial Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.] (Pubitemid 38702844)
49. H.S. Hochster, L.L. Hart, R.K. Ramanathan, B.H. Childs, J.D. Hainsworth, and A.L. Cohn Safety and efficacy of Oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study J Clin Oncol 26 21 2008 Jul 20 3523 3529
50. P. Rougier, J.L. Raoul, J.L. Van Laethem, M. Peeters, C. Husseini, and C. Brezault Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal carcinoma J Clin Oncol 22 14(S) 2004 3513
51. G. Folprecht, M.P. Lutz, P. Schoffski, T. Seufferlein, A. Nolting, and P. Pollert Cetuximab and Irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 3 2006 Mar 450 456 (Pubitemid 43329582)
52. J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, and T. Andre Phase II trial of Cetuximab in combination with fluorouracil, leucovorin, and Oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 33 2007 Nov 20 5225 5232 (Pubitemid 350232254)
53. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 Jul 22 337 345 (Pubitemid 38944402)
54. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, and M. Zampino Cetuximab plus 5-FU/FA/Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first line treatment of metastatic colorectal cancer (mCRC): Opus a randomized phase II study J Clin Oncol 25 18S 2007 4035
55. A.F. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y.A. Abubakr, and M.P. Lutz EPIC: phase III trial of Cetuximab plus Irinotecan after fluoropyrimidine and Oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 14 2008 May 10 2311 2319
56. E. Van Cutsem, M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, and J. Maurel Randomized phase III study of Irinotecan and 5-FU/FA with or without Cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial J Clin Oncol (Meeting Abstracts) 25 Suppl. 18 June 20, 2007 4000
57. J.R. Hecht, A. Patnaik, J. Berlin, A. Venook, I. Malik, and S. Tchekmedyian Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer 110 5 2007 Sep 1 980 988 (Pubitemid 47312862)
58. E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, and B. Neyns Open-label phase III trial of Panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer J Clin Oncol 25 13 2007 May 1 1658 1664 (Pubitemid 46797944)
59. E. Van Cutsem, S. Siena, Y. Humblet, J.L. Canon, J. Maurel, and E. Bajetta An open-label, single-arm study assessing safety and efficacy of Panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Ann Oncol 19 1 2008 Jan 92 98
60. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 9 May 6, 1998 675 684 (Pubitemid 28222141)
61. M. Esteller, S. Gonzalez, R.A. Risques, E. Marcuello, R. Mangues, and J.R. Germa K-ras and p16 aberrations confer poor prognosis in human colorectal cancer J Clin Oncol 19 2 January 15, 2001 299 304 (Pubitemid 32112840)
62. D.J. Ahnen, P. Feigl, G. Quan, C. Fenoglio-Preiser, L.C. Lovato, and P.A. Bunn Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study Cancer Res 58 6 1998 Mar 15 1149 1158 (Pubitemid 28183202)
63. W.L. Ince, A.M. Jubb, S.N. Holden, E.B. Holmgren, P. Tobin, and M. Sridhar Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 13 July 6, 2005 981 999
64. H.I. Hurwitz, J. Yi, W. Ince, W.F. Novotny, and O. Rosen The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 1 January 1, 2009 22 28
65. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, J.R. Zalcberg, D. Tu, and H.J. Au Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 Nov 15 2040 2048 (Pubitemid 350106711)
66. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, and N.C. Tebbutt K-ras mutations and benefit from Cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 Oct 23 1757 1765
67. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, and D.J. Freeman Wild-type KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 Apr 1 1626 1634
68. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 2009 Sep 8
69. J. Souglakos, J. Philips, R. Wang, S. Marwah, M. Silver, and M. Tzardi Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 3 2009 Aug 4 465 472
70. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, and P. Saletti Wild-type BRAF is required for response to Panitumumab or Cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 2008 Dec 10 5705 5712
71. F. Loupakis, A. Ruzzo, C. Cremolini, B. Vincenzi, L. Salvatore, and D. Santini KRAS codon 61, 146 and BRAF mutations predict resistance to Cetuximab plus Irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 4 2009 Aug 18 715 721
72. D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson, C.J.H. Van de Velde, and M. Nicolson Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 1 July 6, 2006 11 20
73. V.P. Khatri, K.G. Chee, and N.J. Pertrelli Modern multimodality approach to hepatic colorectal metastases: solutions and controversies Surg Oncol 16 2007 71 83 (Pubitemid 46880341)
74. B. Nordlinger, and S. Benoist Benefits and risks of neoadjuvant therapy for liver metastases J Clin Oncol 24 31 2006 4954 4955 (Pubitemid 46631395)
75. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, and P. Rougier Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 2008 Mar 22 1007 1016 (Pubitemid 351392040)
76. E.K. Abdalla, R. Adam, A.J. Bilchik, D. Jaeck, J.N. Vauthey, and D. Mahvi Improving resectability of hepatic colorectal metastases: expert consensus statement Ann Surg Oncol 13 10 2006 1271 1280 (Pubitemid 44435793)
77. H. Bismuth, R. Adam, F. Levi, C. Farabos, F. Waechter, and D. Castaing Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 224 4 1996 Oct 509 520 discussion 20-22
78. S.R. Alberts, W.L. Horvath, W.C. Sternfeld, R.M. Goldberg, M.R. Mahoney, and S.R. Dakhil Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study J Clin Oncol 23 36 2005 9243 9249
79. R. Adam, E. Avisar, A. Ariche, S. Giachetti, D. Azoulay, and D. Castaing Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal Ann Surg Oncol 8 4 2001 May 347 353 (Pubitemid 32422861)
80. D. Hind, P. Tappenden, I. Tumur, E. Eggington, P. Sutcliffe, and A. Ryan The use of Irinotecan, Oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation Health Technol Assess 12 15 2008
81. C. Tournigand, T. Andre, E. Achille, G. Lledo, M. Flesh, and D. Mery-Mignard FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 Jan 15 229 237 (Pubitemid 41095086)
82. G. Masi, F. Loupakis, L. Pollina, E. Vasile, S. Cupini, and S. Ricci Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluouracil/leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) followed by radical surgery of metastases Ann Surg 249 3 2009 420 425
83. R.D. Sullivan, J.W. Norcross, and E. Watkins Jr. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion N Engl J Med 270 1964 Feb 13 321 327
84. M.M. Kemeny, D.A. Goldberg, S. Browning, G.E. Metter, P.J. Miner, and J.J. Terz Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study Cancer 55 6 1985 Mar 15 1265 1270 (Pubitemid 15143402)
85. D. Zorzi, A. Laurent, T.M. Pawlik, G.Y. Lauwers, J.N. Vauthey, and E.K. Abdalla Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases Br J Surg 94 3 2007 274 286 (Pubitemid 46423843)
86. N. Kemeny, Y. Huang, A.M. Cohen, W. Shi, J.A. Conti, and M.F. Brennan Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer N Engl J Med 341 27 1999 Dec 30 2039 2048 (Pubitemid 30035952)
87. C. Rudroff, A. Altendorf-Hoffmann, R. Stangl, and J. Scheele Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases Langenbecks Arch Surg 384 3 1999 Jun 243 249 (Pubitemid 29309067)
88. M.M. Kemeny, H. Battifora, D.W. Blayney, G. Cecchi, D.A. Goldberg, and L.A. Leong Sclerosing cholangitis after continuous hepatic artery infusion of FUDR Ann Surg 202 2 1985 Aug 176 181 (Pubitemid 15041717)
89. R.C. Martin, M.J. Edwards, and K.M. McMasters Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver Am J Surg 188 6 2004 Dec 714 721
90. R.L. Nelson, and S. Freels Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver Cochrane Database Syst Rev [Syst Rev] 4 2006
91. J. Figueras, C. Valls, A. Rafecas, J. Fabregat, E. Ramos, and E. Jaurrieta Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases Br J Surg 88 7 2001 Jul 980 985 (Pubitemid 34015581)
92. G. Portier, D. Elias, O. Bouche, P. Rougier, J.F. Bosset, and J. Saric Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 31 2006 Nov 1 4976 4982 (Pubitemid 46631399)
93. B. Langer, H. Bleiberg, R. Labianca, L. Shepherd, D. Nitti, and S. Marsoni Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial Proc Am Soc Clin Oncol. [Abstract] 21 2002 149a
94. E. Mitry, A.L. Fields, H. Bleiberg, R. Labianca, G. Portier, and D. Tu Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 30 2008 Oct 20 4906 4911
95. H.J. Mackay, K. Billingsley, S. Gallinger, S. Berry, A. Smith, and R. Yeung A multicenter phase II study of "adjuvant" Irinotecan following resection of colorectal hepatic metastases Am J Clin Oncol 28 6 2005 Dec 547 554 (Pubitemid 41790004)
96. L.D. DeLeve, H.M. Shulman, and G.B. McDonald Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis 22 1 2002 Feb 27 42
97. F.C. Willmot, and G.W. Robertson Senecio disease, or cirrhosis of the liver due to senecio poisoning Lancet 2 1920 848 849
98. G.B. McDonald, M.S. Hinds, L.D. Fisher, H.G. Schoch, J.L. Wolford, and M. Banaji Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 118 4 1993 Feb 15 255 267 (Pubitemid 23046384)
99. S. Hasegawa, K. Horibe, T. Kawabe, K. Kato, S. Kojima, and T. Matsuyama Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors Bone Marrow Transplant 22 12 1998 Dec 1191 1197 (Pubitemid 29021129)
100. H.M. Shulman, L.B. Fisher, H.G. Schoch, K.W. Henne, and G.B. McDonald Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 19 5 1994 May 1171 1181
101. Y. Sato, Y. Asada, S. Hara, K. Marutsuka, K. Tamura, and T. Hayashi Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation Histopathology 34 1 1999 Jan 66 70 (Pubitemid 29049079)
102. L.D. DeLeve, X. Wang, G.C. Kanel, Y. Ito, N.W. Bethea, and M.K. McCuskey Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome Hepatology 38 4 2003 Oct 900 908 (Pubitemid 37221673)
103. L.D. Deleve, X. Wang, J. Tsai, G. Kanel, S. Strasberg, and Z.A. Tokes Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition Gastroenterology 125 3 2003 Sep 882 890 (Pubitemid 37070704)
104. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, and M. Le Charpentier Severe hepatic sinusoidal obstruction associated with Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 3 2004 Mar 460 466 (Pubitemid 38444550)
105. J.N. Vauthey, T.M. Pawlik, D. Ribero, T.T. Wu, D. Zorzi, and P.M. Hoff Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 13 2006 2065 2072 (Pubitemid 46622116)
106. T. Aloia, M. Sebagh, M. Plasse, V. Karam, F. Levi, and S. Giacchetti Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus Oxaliplatin in colorectal cancer liver metastases J Clin Oncol 24 31 2006 4983 4990 (Pubitemid 46631400)
107. Julie C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, et al. Pathological analysis of hepatic injury after Oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. in: 2007 Gastrointestinal cancers symposium, Orlando, Florida; 2007.
108. Brouquet A, Scatton O, Zalinski S, Terris B, Brezault C, Mallet V, et al., Severe sinusoidal obstrctuction syndrome correlates with worse postoperative outcome after major liver resection and could be predicted preoperatively. In: 8th World Congress of the International Hepato Pancreato Biliary Associstion, Mumbai, India; 2008, 27/2/08-2/3/08.
109. T. Saito, K. Misawa, and S. Kawata 1. Fatty liver and non-alcoholic steatohepatitis Intern Med 46 2 2007 101 103
110. C.P. Day Non-alcoholic fatty liver disease: current concepts and management strategies Clin Med 6 1 2006 Jan-Feb 19 25
111. B.A. Neuschwander-Tetri, and S.H. Caldwell Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 5 2003 May 1202 1219 (Pubitemid 36538699)
112. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 6 2005 Jun 1313 1321 (Pubitemid 40770284)
113. R. Vetelainen, A.K. van Vliet, and T.M. van Gulik Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy Ann Surg 245 1 2007 Jan 44 50 (Pubitemid 46035434)
114. L. McCormack, H. Petrowsky, W. Jochum, K. Furrer, and P.A. Clavien Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study Ann Surg 245 6 2007 Jun 923 930 (Pubitemid 46809294)
115. P.D. Peppercorn, R.H. Reznek, P. Wilson, M.L. Slevin, and R.K. Gupta Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer Br J Cancer 77 11 1998 Jun 2008 2011 (Pubitemid 28254648)
116. D.A. Kooby, Y. Fong, A. Suriawinata, M. Gonen, P.J. Allen, and D.S. Klimstra Impact of steatosis on perioperative outcome following hepatic resection J Gastrointest Surg 7 8 2003 Dec 1034 1044 (Pubitemid 37524071)
117. A.A. Parikh, B. Gentner, T.T. Wu, S.A. Curley, L.M. Ellis, and J.N. Vauthey Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy J Gastrointest Surg 7 8 2003 Dec 1082 1088 (Pubitemid 37526731)
118. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, and B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 9 1999 Sep 2467 2474 (Pubitemid 29420675)
119. F.G. Fernandez, J. Ritter, J.W. Goodwin, D.C. Linehan, W.G. Hawkins, and S.M. Strasberg Effect of steatohepatitis associated with Irinotecan or Oxaliplatin pretreatment on resectability of hepatic colorectal metastases.[see comment] Journal of the American College of Surgeons 200 6 2005 Jun 845 853 (Pubitemid 40744790)
120. H. Shimizu, N. Mitsuhashi, M. Ohtsuka, H. Ito, F. Kimura, and S. Ambiru Vascular endothelial growth factor and angiopoietins regulate sinusoidal regeneration and remodeling after partial hepatectomy in rats World J Gastroenterol 11 46 2005 Dec 14 7254 7260 (Pubitemid 43137672)
121. E. Taniguchi, S. Sakisaka, K. Matsuo, K. Tanikawa, and M. Sata Expression and Role of Vascular Endothelial Growth Factor in Liver Regeneration After Partial Hepatectomy in Rats J Histochem Cytochem 49 1 January 1, 2001 121 130
122. H. Oe, T. Kaido, A. Mori, H. Onodera, and M. Imamura Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats Hepatogastroenterology 52 65 2005 Sep-Oct 1393 1397 (Pubitemid 41391000)
123. M. Bockhorn, M. Goralski, D. Prokofiev, P. Dammann, P. Grunewald, and M. Trippler VEGF is important for early liver regeneration after partial hepatectomy J Surg Res 138 2 2007 Apr 291 299 (Pubitemid 46365724)
124. A. Natarajan, B. Wagner, and M. Sibilia The EGF receptor is required for efficient liver regeneration Proc Natl Acad Sci USA 104 43 2007 Oct 23 17081 17086 (Pubitemid 350210995)
125. C. Mitchell, M. Nivison, L.F. Jackson, R. Fox, D.C. Lee, and J.S. Campbell Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration J Biol Chem 280 4 January 28, 2005 2562 2568 (Pubitemid 40189358)
126. S. Kiso, S. Kawata, S. Tamura, Y. Inui, Y. Yoshida, and Y. Sawai Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy Gastroenterology 124 3 2003 Mar 701 707 (Pubitemid 36268489)
127. G. Van Buren II, A.D. Yang, N.A. Dallas, M.J. Gray, S.J. Lim, and L. Xia Effect of molecular therapeutics on liver regeneration in a murine model J Clin Oncol 26 11 April 10, 2008 1836 1842
128. M. D'Angelica, P. Kornprat, M. Gonen, K.Y. Chung, W.R. Jarnagin, and R.P. DeMatteo Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study Ann Surg Oncol 14 2 2007 Feb 759 765 (Pubitemid 46175324)
129. S.K. Reddy, M.A. Morse, H.I. Hurwitz, J.C. Bendell, T.J. Gan, and S.E. Hill Addition of bevacizumab to Irinotecan- and Oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases J Am Coll Surg 206 1 2008 Jan 96 106 (Pubitemid 350267242)
130. H.D. Gonzalez, and J. Figueras Practical questions in liver metastases of colorectal cancer: general principles of treatment HPB (Oxford) 9 4 2007 251 258 (Pubitemid 47263958)
131. A.J. Bilchik, and J.R. Hecht Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based? J Clin Oncol 26 11 2008 Apr 10 1786 1788
132. A.J. Bilchik, G. Poston, S.A. Curley, S. Strasberg, L. Saltz, and R. Adam Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note J Clin Oncol 23 36 December 20, 2005 9073 9078